RECORMON 2000 IU

País: Israel

Idioma: inglés

Fuente: Ministry of Health

Ingredientes activos:

EPOETIN BETA 2000 IU / 0.3 ML

Disponible desde:

ROCHE PHARMACEUTICALS (ISRAEL) LTD

Código ATC:

B03XA01

formulario farmacéutico:

SOLUTION FOR INJECTION

Vía de administración:

I.V, S.C

Fabricado por:

ROCHE DIAGNOSTICS GmbH ,GERMANY

Grupo terapéutico:

ERYTHROPOIETIN

indicaciones terapéuticas:

Treatment of anemia associated with chronic renal failure (renal anemia) in patients on dialysis. Treatment of symptomatic renal anemia in patients not yet undergoing dialysis. Increasing the yield of autologous blood from patients in a pre-donation program. Its use in this indication must be balanced against the reported increased risk of thromboembolic events. Treatment should only be given to patients with moderate anemia (Hb 10-13 g/dl (6.21- 8.07 mmol/l) no iron deficiency) or when blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). Treatment of anemia in adult patients with solid tumors and treated with platinum-based chemotherapy prone to induce anemia (cisplatin 75 mg/m2/cycle carboplatin: 350 mg/m2/cycle). Treatment of anemia in adult patients with multiple myeloma low grade non-Hodgkin's lymphoma or chronic lymphocytic leukemia who have a relative

Fecha de autorización:

2009-06-01